Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Frontiers in Immunology
|
February 23, 2026
Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages
Carla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Clinical Gastroenterology
|
June 13, 2020
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma
Álvaro Díaz-González, Ernest Belmonte, Víctor Sapena, et al.
Cancers
|
July 14, 2023
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction
Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, et al.
United European Gastroenterology Journal
|
July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
Álvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials
Álvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2025
Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.]
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2026
Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404]
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Journal of Patient-Reported Outcomes
|
April 8, 2025
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial
Manuel De la Torre-Aláez, Ana Matilla, María Varela, et al.
Journal of Hepatology
|
April 5, 2026
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]
Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Frontiers in Immunology
|
February 23, 2026
Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages
Carla Fuster-Anglada, Josep Corominas, Aida Marsal, et al.
Journal of Clinical Gastroenterology
|
June 13, 2020
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma
Álvaro Díaz-González, Ernest Belmonte, Víctor Sapena, et al.
Cancers
|
July 14, 2023
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction
Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, et al.
United European Gastroenterology Journal
|
July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
Álvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials
Álvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2025
Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.]
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2026
Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404]
Marta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Journal of Patient-Reported Outcomes
|
April 8, 2025
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial
Manuel De la Torre-Aláez, Ana Matilla, María Varela, et al.
Journal of Hepatology
|
April 5, 2026
Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654]
Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, et al.
Page
of 3